Stay updated with breaking news from Section Head. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nonprofit’s Scientific and Medical Advisory Board Represented by Foremost Leaders in Pancreatic Cancer Field LOS ANGELES, Calif. – (July 18, [...] READ MORE
/PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, proudly announces the addition of...
Randomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023Recently Published Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination...
Metrion Biosciences Limited (“Metrion”), is a specialist ion channel contract research and drug discovery company.
Randomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023 Recently Published Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination Company Intends to File for Accelerated FDA Approval for the Combination Based on Mature Data from RAMP 201 and the FRAME Trial